[3] In a September 2007 club deal, the company was acquired by a consortium of private equity firms consisting of The Blackstone Group, Goldman Sachs, Kohlberg Kravis Roberts L.P. and TPG Capital, after which Biomet ceased trading on NASDAQ.

However, in October 2014, EU antitrust regulators opened an investigation into Zimmer's bid on the grounds that the deal may lead to substantial decreases in competition in certain markets.

[7] These included LactoSorb, a fixation system made of completely resorbable material for guided bone regeneration, titanium plates and screws for craniomaxillofacial fixation, instruments for craniomaxillofacial and orthopedic procedures and hard tissue replacements made out of biocompatible polymers, as used in cranial defects.

[9] In 2012, Biomet paid more than $22 million to settle SEC and Department of Justice violations of the Foreign Corrupt Practices Act (FCPA).

[11] These violations are also correlated with the first time a whistleblower received monetary compensation for reporting an entity to the SEC that led to a successful conviction.